Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Saude em Debate |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886 |
Resumo: | ABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems. |
id |
CBES-1_1638414ba8eadc1eb5eff8ee9fc00d80 |
---|---|
oai_identifier_str |
oai:scielo:S0103-11042022000300886 |
network_acronym_str |
CBES-1 |
network_name_str |
Saude em Debate |
repository_id_str |
|
spelling |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and BrazilHealth policyTechnologyHigh-CostPublic healthABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems.Centro Brasileiro de Estudos de Saúde2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886Saúde em Debate v.46 n.134 2022reponame:Saude em Debateinstname:Centro Brasileiro de Estudos de Saudeinstacron:CBES10.1590/0103-1104202213422info:eu-repo/semantics/openAccessVicente,GeisonCalnan,MichaelRech,NorbertoLeite,Silvanaeng2022-09-08T00:00:00Zoai:scielo:S0103-11042022000300886Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0103-1104&lng=en&nrm=isohttps://old.scielo.br/oai/scielo-oai.phprevista@saudeemdebate.org.br2358-28980103-1104opendoar:2022-09-08T00:00Saude em Debate - Centro Brasileiro de Estudos de Saudefalse |
dc.title.none.fl_str_mv |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
title |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
spellingShingle |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil Vicente,Geison Health policy Technology High-Cost Public health |
title_short |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
title_full |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
title_fullStr |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
title_full_unstemmed |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
title_sort |
Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil |
author |
Vicente,Geison |
author_facet |
Vicente,Geison Calnan,Michael Rech,Norberto Leite,Silvana |
author_role |
author |
author2 |
Calnan,Michael Rech,Norberto Leite,Silvana |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Vicente,Geison Calnan,Michael Rech,Norberto Leite,Silvana |
dc.subject.por.fl_str_mv |
Health policy Technology High-Cost Public health |
topic |
Health policy Technology High-Cost Public health |
description |
ABSTRACT Although the National Health Service (NHS) and the Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. This paper aimed to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee access and sustainability to High-Price Medicines (HPMs) in Brazil and England. We performed an integrative literature review in electronic databases, supplemented by grey literature searched on governmental platforms (laws, decrees, ordinances, and resolutions). A total of Forty-seven articles and seven policies were selected and categorized for analysis. The results showed that both countries apply distinct policies to ensure access to HPMs, among them, policies to define price and reimbursement and actions to regulate the use inside the system. Also, these countries apply distinct policies to their sustainability as local partnerships for product development in Brazil and confidential managed agreements with multinational industries in the England. In conclusion, despite similarities in principles, these countries have been proposing and applying distinct pharmaceutical policies to maintain access and ensure the sustainability of their health systems. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042022000300886 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0103-1104202213422 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Centro Brasileiro de Estudos de Saúde |
publisher.none.fl_str_mv |
Centro Brasileiro de Estudos de Saúde |
dc.source.none.fl_str_mv |
Saúde em Debate v.46 n.134 2022 reponame:Saude em Debate instname:Centro Brasileiro de Estudos de Saude instacron:CBES |
instname_str |
Centro Brasileiro de Estudos de Saude |
instacron_str |
CBES |
institution |
CBES |
reponame_str |
Saude em Debate |
collection |
Saude em Debate |
repository.name.fl_str_mv |
Saude em Debate - Centro Brasileiro de Estudos de Saude |
repository.mail.fl_str_mv |
revista@saudeemdebate.org.br |
_version_ |
1754209002153050112 |